SI
SI
discoversearch


 Biotech / Medical: Genomic Health: predicting the course of an individual's can  
Posts: 33 | Member SubjectMarks: 12 | No Bans

Share This Board Moderated By: A.J. Mullen -- (Moderated) -- Started: 11/29/2006 11:19:22 PM  Revision History

The approach is very simple. Genomic Health have looked at the genetic structure of samples taken from tumours of patients going back 15(?) years. They know the case histories of the patients, so they are able to make statistical associations between the genetic structure and the progression of the disease. Their first test is for breast cancer.


They've developed a screen for twenty six(?) genes. A biopsy is taken from a cancerous tumor and sent to Genomic Health. They screen it against a panel of twenty six(?) genes and produce a score that estimates likelihood of recurrence. This allows the patient and doctor to make informed decisions concerning treatment.

Chemotherapy is currently recommended for more than 90% of women who have breast cancer. 83% of women who have surgery and hormone therapy alone, without chemotherapy, will not have recurrence within ten years. Chemotherapy increases that probability to 87%. For those in the 17% that would have recurrence then, chemotherapy can make a substantial difference. The problem is in deciding who's in which group. Oncotype DX (the name given to the test) helps women get the treatment appropriate for them.

The test costs $3 460, which is a lot less than either a course of chemotherapy, or the cost of treating mestastisized cancer. Medicare is reimbursing as well as Kaiser, Primera, Humana, and Aetna. They still have a way to go. They only have 30% of insurers signed up so far. I think they have only been marketing the test for a year or so.

The FDA is probably going to regulate tests of this sort. Genomic Health has validated their predictions and published the results in the New England Journal of Medicine. They welcome the regulation.

The technique can be extended to other cancers. They are working on prostate, colon, renal, and NSCLC. Together their target market is around half a million a year.

The company has a very strong management team. The CEO, Randy Scott is from Incyte, three senior managers are from Genentech, and another was with Guidant and Applied Biosystems.

More information is available at the company's website, www.genomichealth.com. Any discrepancy between my summary and the website is likely a result of my error.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsDate
33Genomic Health's Oncotype DX(R) Colon Cancer Test Predicts Individualized ReA.J. Mullen-05/15/2009 09:43 AM
32BTW, the competition you mentioned Mammaprint (I believe) is pretty much dead. Htradeyourstocks-05/06/2008 11:44 AM
31You make some good points Brad. I like the technology and hope it is used in guA.J. Mullen-04/26/2008 05:09 PM
30Ashley, Thanks for starting this thread. I'm disappointed to hear that youSI Brad-04/26/2008 03:20 PM
29Short interest has gone up significantly in the last few months nasdaq.com SI Brad-04/26/2008 02:38 PM
28I have been looking for a promising stock for several years and I've finallySI Brad-02/27/2008 10:39 AM
27Genomic Jumps on Better-Than-Expected 4Q Wednesday February 6, 11:03 am ET Genomtnsaf-02/07/2008 01:07 AM
26GHDX real news biz.yahoo.com  steve Steve Lokness-10/23/2007 11:25 AM
25Thanks for being frank. ido idos-03/27/2007 04:47 PM
24Having started this thread and having stated that I owned shares, I should also A.J. Mullen-03/27/2007 04:13 PM
23AP Genomic Rises on Upgrade to 'Outperform' Tuesday March 27, 12:52 pm Eidos-03/27/2007 01:44 PM
22Heavy buying by BAKER BROTHERS at $18.25 secform4.com  idos-02/15/2007 03:21 AM
21Thanks for that. It'll be interesting to see how it plays out. Ashley A.J. Mullen-02/08/2007 10:39 AM
20Some competition for Oncotype DX of GHDX: nytimes.com  idos-02/08/2007 08:59 AM
19Genomic Health Announces Fourth Quarter and Year-end 2006 Financial Results and A.J. Mullen-02/07/2007 11:52 AM
18Genomic Health shares tumbled 9% to $21.71. Analysts at Lehman Brothers cut theiidos-01/17/2007 10:32 AM
17<Shame you missed the dip at the turn of the year. That would have been a gooidos-01/12/2007 02:28 PM
16I bought it this time last year, just after the JP Morgan Conference. It was goA.J. Mullen-01/12/2007 12:30 PM
15Ashley did you see this? Link: SI Message 23177516 ido idos-01/12/2007 08:41 AM
14Well done (position in GHDX)! I'll keep watching&waiting for an entry poidos-01/12/2007 01:46 AM
13I agree with you that personalised medicine is the way of the future. I do haveA.J. Mullen-01/11/2007 12:49 PM
12I'm interested because of the importance of the concept of pre screening befidos-01/11/2007 04:54 AM
11I listened to the JP Morgan presentation live. It should be archived within an A.J. Mullen-01/10/2007 06:12 PM
10Thanks for that Idos. It's good to see someone else is interested. Ashley A.J. Mullen-01/10/2007 12:21 PM
9GHDX going up 13% on the news: Genomic Health cancer test wins UnitedHealth contidos-01/10/2007 10:36 AM
8Genomic Health to Present at 2007 JPMorgan Healthcare Conference Wednesday JanuaA.J. Mullen-01/03/2007 11:25 AM
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.